SIGLEC1 and neoplasm: Both peptide and protein targeting to CD169 stimulated potent anti-tumor CD8+ T cell responses that were as efficient to prevent outgrowth of B16-OVA melanoma cells, indicating that the generated OVA specific CD8+ T cell homed to the tumor.